Latest Headlines

Latest Headlines

Celgene, Novartis back precision medicine analytics startup after recent board addition from CMS

COTA has staked out its claim to having the first and only digital classification system to unite a number of significant prognostic variables into one digital code aimed at guiding healthcare provider and payer decision-making.

Varian to spin off imaging components biz as publicly traded company by year-end

Varian Medical Systems' share price is virtually unchanged from two years ago. That's despite the growing consensus that its proton therapy offers more precise and less toxic treatment for cancer patients than traditional radiation. It's now planning to spin off its imaging components business to help unlock some of that value.

Siemens buys German liquid biopsy startup to enter molecular oncology Dx

Siemens is making good on its commitment earlier this month to expand in molecular diagnostics with the acquisition of Neo New Oncology. The German startup has a genomic diagnostic platform to enable physicians to better select targeted cancer therapies. Its offering includes assays for both tissue and bodily fluids--and it has a liquid biopsy test to create a profile of solid tumors.

Interventional oncology player BTG to acquire cryoablation upstart for up to $110M

Interventional oncology specialist BTG is working to make med tech more relevant in oncology--something it's got a shot at doing as localized treatment delivery and minimally invasive surgical techniques continue to emerge.

Pfizer backs biology-guided cancer radiotherapy startup in $46M Series B round

Reflexion Medical has raised $46 million to develop the first biology-guided radiotherapy system that offers targeted cancer treatment. Last fall, the Hayward, CA-based startup said it had created a prototype device that was ready to go into the clinic. This Series B infusion is earmarked for expanding the company's engineering, regulatory and commercial groups.

Intel's life sciences head moves camps to lead Precision Medicine Initiative research

Back in February, tech giant Intel said that it would launch a new program under President Barack Obama's Precision Medicine Initiative (PMI) to improve data analytics for genomics research. Now, the company's general manager of Health & Life Sciences is moving camps and joining the National Institutes of Health to lead PMI research.

IBM Watson Health creates American Cancer Society, global health initiatives

IBM will announce a pair of new Watson Health initiatives. One is with the American Cancer Society to apply the power of artificial intelligence to patient-oriented healthcare information, the other is an effort dubbed IBM Health Corps that aims to apply Watson's AI capabilities to better solve global health challenges.

FDA nod for tissue containment in power morcellation comes amid ongoing review of cancer concerns

Irish startup Advanced Surgical Concepts has nabbed an FDA nod for its tissue containment system for use with certain laparoscopic power morcellators. The regulatory go-ahead falls under the agency's de novo process that's reserved for low- to moderate-risk devices that are novel.

Johns Hopkins scientists help explain why cancer stem cells survive in low oxygen

Work on human breast cancer cells and mice has helped researchers at the Johns Hopkins University explain how some cancer stem cells (CSCs) thrive when oxygen supply is limited. CSCs are a major source for chemotherapy resistance and tumors spreading, and this research highlights a potential pathway that may be blocked to prevent their proliferation.

GE-backed deep learning startup Arterys bumps up Series A to $12M+ as it nears cardio launch, goes into oncology

Medical imaging deep learning startup Arterys has a major partnership with GE and a cardio product launch teed up as part of that for this fall. Now, it's lined up a more than $12 million Series A financing to help it transition into its next field: oncology. The San Francisco, CA-based startup had previously disclosed a smaller sum for that Series A of $7 million late last year.